Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrimack Pharmaceuticals has enrolled last patient in one group of the two cohorts of Phase 2 study of MM-121 in HER2-negative breast cancer.
Subscribe to our email newsletter
The efficacy of MM-121 in combination with paclitaxel compared to paclitaxel alone in the neoadjuvant setting of HER2-negative breast cancer will be assessed in the study.
MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumour growth and survival.
Merrimack translational research co-founder and vice president Gavin MacBeath said the study helps in finding out the efficacy of MM-121 in patients who have not yet seen prior therapies for their disease.
"It also gives us the opportunity to assess biomarkers at an early stage in cancer treatment, which we believe will allow us to better understand biomarker profiles being explored for MM-121," MacBeath added.
A total of 100 HER2-negative patients with either estrogen receptor (ER) and/or progesterone receptor (PR) positive markers are enrolled in the first cohort.
Enrollment is going on in the second cohort with patients with triple negative breast cancer (TNBC), which is diagnosed when a patient’s tumour tests negative for HER2, ER and PR biomarkers.
The company expects final results from the first cohort in the second half of 2013 and second cohort in 2014.